Molecular Abnormalities and Carcinogenesis in Barrett’s Esophagus: Implications for Cancer Treatment and Prevention
Authors:
- Thaís Cabral de Melo VianaTVThaís Cabral de Melo Viana
- Eric Toshiyuki NakamuraENEric Toshiyuki Nakamura
- Amanda ParkAPAmanda Park
- Kaique Flávio Xavier Cardoso FilardiKFKaique Flávio Xavier Cardoso Filardi
- Rodrigo Moisés de Almeida LeiteRLRodrigo Moisés de Almeida Leite
- Luiz Fernando Sposito Ribeiro BaltazarLBLuiz Fernando Sposito Ribeiro Baltazar
- Pedro Luiz Serrano Usón JuniorPedro Luiz Serrano Usón Junior
- Francisco TustumiFrancisco Tustumi
Open Access
Abstract
Background: Barrett’s esophagus (BE) is described by the transformation of the normal squamous epithelium into metaplastic columnar epithelium, driven by chronic gastroesophageal reflux disease (GERD). BE is a recognized premalignant condition and the main precursor to esophageal adenocarcinoma (EAC). Understanding the molecular mechanisms underlying BE carcinogenesis is crucial for improving prevention, surveillance, and treatment strategies. Methods: This narrative review examines the molecular abnormalities associated with the progression of BE to EAC. Results: This study highlights inflammatory, genetic, epigenetic, and chromosomal alterations, emphasizing key pathways and biomarkers. BE progression follows a multistep process involving dysplasia and genetic alterations such as TP53 and CDKN2A (p16) mutations, chromosomal instability, and dysregulation of pathways like PI3K/AKT/mTOR. Epigenetic alterations, including aberrant microRNA expression or DNA methylation, further contribute to this progression. These molecular changes are stage-specific, with some alterations occurring early in BE during the transition to high-grade dysplasia or EAC. Innovations in chemoprevention, such as combining proton pump inhibitors and aspirin, and the potential of antireflux surgery to halt disease progression are promising. Incorporating molecular biomarkers into surveillance strategies and advancing precision medicine may enable earlier detection and personalized treatments. Conclusions: BE is the primary preneoplastic condition for EAC. A deeper understanding of its molecular transformation can enhance surveillance protocols, optimize the management of gastroesophageal reflux inflammation, and refine prevention and therapeutic strategies, ultimately contributing to a reduction in the global burden of EAC.Keywords
This publication has 173 references indexed in Scilit:
- Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progressionCancer Medicine, 2021
- High‐resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinomaInternational Journal of Cancer, 2019
- Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNF‐αEMBO Molecular Medicine, 2012
- Alu and Satα hypomethylation in Helicobacter pylori‐infected gastric mucosaeInternational Journal of Cancer, 2010
- Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factorsInternational Journal of Cancer, 2008
- Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesisCancer, 2007
- Inflammation and cancer: An ancient link with novel potentialsInternational Journal of Cancer, 2007
- Chronic inflammation and oxidative stress in human carcinogenesisInternational Journal of Cancer, 2007
- Expression and function of interleukin‐6 in epithelial cellsJournal of Cellular Biochemistry, 1991
- Chronic peptic ulcerz of the œophagus and ‘œsophagitis’British Journal of Surgery, 1950